Chaparral Labs
back to search

protein

E3 ubiquitin-protein ligase ARIH1

ARIH1
protein:Q9Y4X5disease:adad:direction:ambiguous

Gene

ARIH1

Organism

Homo sapiens(9606)

Length

557 aa

Mass

64,118 Da

AI summarysource-grounded · cited inline
claude-haiku-4-5-20251001

ARIH1 (E3 ubiquitin-protein ligase ARIH1) is an atypical E3 ubiquitin ligase that catalyzes ubiquitination of target proteins in conjunction with ubiquitin-conjugating enzyme UBE2L3 (UniProt: Q9Y4X5). It functions within cullin-RING ubiquitin ligase (CRL) complexes to initiate ubiquitination of CRL substrates, with the initial ubiquitin subsequently elongated by CDC34 and UBE2R. ARIH1 is activated upon binding to neddylated CRL complexes and also regulates protein translation in response to DNA damage through ubiquitination of EIF4E2.

ARIH1 participates in cellular protein quality control and nuclear organization pathways. The protein mediates ubiquitination of SUN2, a linker of nucleoskeleton and cytoskeleton (LINC) complex member, influencing nuclear localization and morphology. No disease associations are documented in UniProt for ARIH1.

In Alzheimer's disease brain tissue, ARIH1 shows ambiguous regulation across subcellular fractions in post-mortem AD compared to age-matched controls (Chaparral AD proteomics). Analysis of human brain tissue by tandem mass tag proteomics across four subcellular fractions yielded a mean log2 fold-change of −0.55, indicating modest overall reduction, though directionality varies by cellular compartment. This suggests potential compartment-specific dysregulation in AD pathology.

Generated from the curated entity record below. May contain errors — verify against source links.

Proteomics Evidence · AD

⚠ Ambiguous — detected in AD samples, direction unclear across fractions

P3

not detected

P2

+0.273

S2

-1.370

S3

not detected

Mean log₂FC across detected fractions: -0.5485 (2 of 4 fractions detected)

Human post-mortem AD brain vs age-matched controls, TMT-labeled, 4 subcellular fractions (P2, P3, S2, S3), DDA proteomics.

Related Publications

Browse all →

Function

E3 ubiquitin-protein ligase, which catalyzes ubiquitination of target proteins together with ubiquitin-conjugating enzyme E2 UBE2L3 (PubMed:15236971, PubMed:21532592, PubMed:23707686, PubMed:24076655, PubMed:27565346). Acts as an atypical E3 ubiquitin-protein ligase by working together with cullin-RING ubiquitin ligase (CRL) complexes and initiating ubiquitination of CRL substrates: associates with CRL complexes and specifically mediates addition of the first ubiquitin on CRLs targets (PubMed:27565346). The initial ubiquitin is then elongated by CDC34/UBE2R1 and UBE2R2 (PubMed:27565346). E3 ubiquitin-protein ligase activity is activated upon binding to neddylated cullin-RING ubiquitin ligase complexes (PubMed:24076655, PubMed:27565346). Plays a role in protein translation in response to DNA damage by mediating ubiquitination of EIF4E2, the consequences of EIF4E2 ubiquitination are however unclear (PubMed:25624349). According to a report, EIF4E2 ubiquitination leads to promote EIF4E2 cap-binding and protein translation arrest (PubMed:25624349). According to another report EIF4E2 ubiquitination leads to its subsequent degradation (PubMed:14623119). Acts as the ligase involved in ISGylation of EIF4E2 (PubMed:17289916). In vitro, controls the degradation of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex member SUN2 and may therefore have a role in the formation and localization of the LINC complex, and as a consequence, nuclear subcellular localization and nuclear morphology (PubMed:29689197)

Sources

Last updated 5/8/2026, 6:30:00 AM